Primaa
Primaa is a Paris-based medical imaging AI company that develops CE-IVDR certified deep learning software for pathologists to detect cancer biomarkers in breast and skin tissue slides, selling enterprise site licenses and OEM-embedded algorithms to hospitals and digital pathology platform providers across Europe and the US.
- Company typePrivate
- Founded2018
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Primaa does
Primaa SAS is a Paris-based medical imaging AI company founded in 2018 by pathologist Marie Sockeel, along with co-founders Fanny Sockeel (CEO) and Stéphane Sockeel (CSO). The company develops the Cleo platform, a deep-learning software suite that analyzes digitized Whole Slide Images (WSI) of histopathological tissue to detect and quantify cancer biomarkers. Its commercial portfolio consists of two CE-IVDR marked products: Cleo Breast (breast cancer diagnostics, CE-IVDR certified September 2025) and Cleo Skin (dermatopathology AI, CE-IVDR certified March 2026 as the world's first AI tool in that category). The technology stack combines convolutional neural networks (EfficientNet, RetinaNet) for detection and classification, U-Net architectures for tissue and nuclei segmentation, and a proprietary CycleGAN-based stain adaptation methodology for generalization across scanners and staining protocols. End-to-end pipelines detect invasive carcinoma regions directly on IHC slides without pathologist pre-selection, and compute automated scores for HER2, Ki67, ER/RP, TILs, mitoses, and skin lesion dimensions and margins.
The company monetizes through enterprise software licensing (annual site licenses for hospitals and laboratories) and through technology partnership licensing with digital pathology Image Management System (IMS) providers. Its go-to-market combines direct enterprise sales in Europe with an OEM/embedded distribution model in which Cleo algorithms are integrated into third-party IMS platforms — PathAI's AISight Dx, Proscia's Concentriq, PathPresenter, Gestalt's PathFlow, Lumea's IMS Viewer+, and Sectra. Reported customers include 10+ laboratories and clinics with over 45 users, including Institut Curie, AP-HP, Hôpital Saint-Joseph, Institut Bergonié, multiple French university hospital centers (CHU de Rennes, CHU de Versailles, CHU Grenoble Alpes), Medipath, and ZAS in Belgium, with first US commercial contracts signed in 2025–2026.
Primaa is privately held, has approximately 25 employees, and is based in Paris with its legal entity registered in Orsay, France. Total disclosed funding is approximately €7 million raised in an October 2025 pre-Series A round, backed by Elaia, Malakoff Humanis, Super Capital VC, and Swen Capital Partners, with earlier participation from 50 Partners, Matmut, Pleiade Investissement, Bpifrance, and Elaia. The capital is earmarked for US market entry, FDA certification, and extension of the AI roadmap into additional cancer types including kidney (PD-L1 scoring under the CARE1 trial).
Primaa firmographics
Firmographics- Name
- Primaa
- Legal name
- Primaa SAS
- Website
- https://primaalab.com
- Company type
- Private
- Founded year
- 2018
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Primaa is a Paris-based medical imaging AI company that develops CE-IVDR certified deep learning software for pathologists to detect cancer biomarkers in breast and skin tissue slides, selling enterprise site licenses and OEM-embedded algorithms to hospitals and digital pathology platform providers across Europe and the US.
- Ownership category
- akta.pro rank
Primaa industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
- akta.pro secondary industries
- Medical Imaging AI (HDAAAEAH), Dermatopathology (HLAKACAC), Imaging & Diagnostic Interoperability (DICOM exchange, image sharing, VNA connectivity) (HLACABAM)
Keywords
Where Primaa is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices2 records
Markets served
Primaa business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Operations, Others
Revenue model
- AI Software Licensing: Enterprise licensing of AI diagnostic software (Cleo Breast, Cleo Skin) to hospitals, cancer institutes, and pathology laboratories. Software is integrated into laboratory viewing systems and sold as annual or multi-year subscriptions. Revenue derived from per-laboratory or per-installation licensing fees.
- Technology Partnership Licensing: Licensing of AI algorithms to digital pathology platform providers (Proscia, PathAI, PathPresenter, Gestalt) for integration into their IMS platforms. Revenue generated through technology integration agreements and per-use licensing.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise site license for laboratory/pathology department |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Primaa product offering
Product offeringCore offering
Primaa develops and sells AI-powered diagnostic software for pathologists, primarily the Cleo platform with two CE-IVDR marked products: Cleo Breast (detects invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases on breast tissue whole slide images) and Cleo Skin (detects melanoma, squamous cell carcinoma, basal cell carcinoma with automated lesion and margin measurements on skin tissue). The software is sold as enterprise site licenses and is integrated into existing digital pathology Image Management Systems to automate biomarker scoring and speed cancer diagnosis.
Product overview
Primaa develops an AI-based platform called Cleo for automated and accurate cancer diagnosis using image analysis and deep learning. The portfolio consists of two CE-IVDR marked core products: Cleo Breast for breast cancer diagnostics and Cleo Skin for dermatopathology. Cleo Breast detects Invasive & In Situ Carcinoma, mitoses, calcifications, and lymph node metastases, with additional modules for TILs scoring, nuclear atypia, and IHC quantification (Ki67, ER/RP, HER2). Cleo Skin is the world's first CE-IVDR marked AI for dermatopathology, classifying lesions (melanoma, nevus, SCC, BCC), measuring dimensions and margins, and detecting mitoses and perineural invasion. Both products integrate with major digital pathology platforms (Sectra, Gestalt PathFlow, PathAI, Proscia, PathPresenter) and feature vendor-agnostic, interoperable design with smart work list prioritization for laboratory workflows.
Differentiator
Problem solved
Functional benefit
Brands
- Cleo Breast: AI-powered primary diagnostic solution for breast cancer diagnosis, CE-IVDR marked, detecting invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases.
- Cleo Skin
Products and services
- Cleo Breast AI-powered primary diagnostic solution for breast cancer, CE-IVDR marked. Detects Invasive & In Situ Carcinoma, mitoses, calcifications, and lymph node metastases on digitized breast tissue Whole Slide Images. Includes automated hotspot detection, IHC quantification (Ki67, ER/RP, HER2), TILs scoring, nuclear atypia analysis, and smart work list prioritization for hospital pathology departments.
- Cleo Skin World's first CE-IVDR marked AI solution for dermatopathology. Detects and classifies skin lesions (melanoma, nevus, squamous cell carcinoma, basal cell carcinoma), automatically measures lesion dimensions and excision margins, detects mitoses and perineural invasion in melanoma regions. Deployed at dermatopathology laboratories and skin cancer diagnostic centers.
- Cleo Platform Core AI-based platform for automated and accurate cancer diagnosis using image analysis and deep learning. Improves detection of major cancer biomarkers and guides personalized treatment, providing time-saving workflow integration, performance gains, and enhanced patient outcomes across multiple organ-specific applications.
Quantifiable outcome
- Detection time reduction: -14% for Invasive & In Situ Carcinoma, -50% for Mitoses, -32% for Macro-Metastases
- +7 more outcomes
Companies that use Primaa
Customer profileNamed customers10 records
Segments3 records
Ideal customer profiles3 records
Primaa technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration19 records
AI capability20 records
Feature8 records
Primaa partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered key and core.
- LumeakeyPartnership integrating Primaa's Cleo Skin AI into Lumea's FDA-cleared IMS Viewer+ platform for dermatopathology diagnostics. Cleo Skin provides automated triage, sub-millimeter measurements, and biomarker detection for the four most common skin lesions.
- PathPresenterkeyIntegration of Cleo Skin AI with PathPresenter's FDA 510(k) and CE-IVDR cleared IMS platform. Makes Cleo Skin available to wider global audience of pathologists through PathPresenter's platform, with demos at ASDP 2025.
- ProsciacoreIntegration of Cleo Skin into Proscia's Concentriq platform through Proscia Ready partner alliance. Adds AI-powered skin biomarker detection (mitoses, mitotic hotspots, perineural invasion) and lesion classification to Concentriq's digital pathology capabilities.
- PathAIcoreIntegration of Cleo Breast (CE-IVDR) and Cleo Skin (RUO) into PathAI's AISight Dx Image Management System. Enables pathologists using AISight Dx to access Primaa's AI-powered algorithms for enhanced accuracy and efficiency in breast and skin tissue lesion detection.
- Gestalt DiagnosticscoreStrategic partnership integrating Primaa's Cleo Skin AI into Gestalt's PathFlow digital pathology platform. Enables pathologists to access AI-driven skin cancer detection, lesion classification (melanoma, SCC, BCC), automatic measurements, and case prioritization within PathFlow workflows. Supports primary diagnosis in US (following LDT process) and CE-IVD marking for Europe.
- Gestalt DiagnosticscorePartnership to advance AI-powered skin cancer detection through integrated digital pathology solutions using Gestalt's platform and Primaa's Cleo Skin technology.
- ZAS (Belgium)keyFirst international clinical deployment of Cleo Skin at ZAS hospital group in Belgium, representing Primaa's expansion beyond France into European markets.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Primaa competitors and assessment
Company assessmentRegional players
- Gestalt Diagnostics: US-based IMS vendor (PathFlow) and Primaa integration partner for Cleo Skin. Functions as a regional digital pathology incumbent and distribution partner for US pathology customers.
Broad incumbents
- Indica Labs: US-based digital pathology software provider (HALO platform) with extensive pharma and research customer base. Broad incumbent offering image analysis with overlapping AI quantification capabilities.
- Proscia: US-based digital pathology platform provider (Concentriq) and Proscia Ready partner alliance host. Functions as both a distribution partner (embedding Primaa) and a broader incumbent that develops its own AI roadmap.
Emerging players
- Mindpeak: Germany-based AI pathology company with CE-marked breast and prostate IHC quantification products. Comparable as a European peer in AI biomarker scoring, slightly narrower product scope.
- Aiosyn: Netherlands-based AI pathology company focused on kidney and breast biomarker quantification. Comparable as a European emerging peer in IHC and biomarker AI.
- Lumea: US-based FDA-cleared digital pathology platform (Viewer+) with strong dermatopathology focus. Embedded Primaa Cleo Skin via marketplace integration; comparable in dermatopathology target segment.
Direct peers
- Paige: US-based AI pathology company; first to receive FDA de novo authorization for an AI pathology product (Paige Prostate) and expanding into breast and dermatopathology. Comparable in target market and AI-on-WSI technology.
- Owkin: France-based AI company building pathology AI models for pharma services and diagnostics, with strong federated learning capabilities. Comparable as a French AI pathology peer and competitor for hospital and pharma customers.
- PathAI: US-based AI pathology company developing both AI algorithms and the AISight Dx Image Management System. Direct competitor in breast and dermatopathology AI, and simultaneously a distribution partner for Primaa's Cleo modules.
- Ibex Medical Analytics: Israel-based AI pathology company with multiple CE-marked products (Galen Breast, Galen Prostate, Galen Gastric) and strong clinical deployments. Directly comparable in product scope (multi-organ AI on WSIs) and customer base (hospital pathology labs).
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Primaa social profiles
Digital presencePrimaa compliance and trust
Trust signalCompliance4 records
Primaa financial estimates
Financial estimateRevenue estimate
Valuation estimate
Primaa leadership team
Management profileNumber of profiles
Profiles9 records
Primaa funding detail
Funding detailFunding overview
Funding rounds1 record
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Primaa M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Primaa
What does Primaa do?
Primaa develops and sells AI-powered diagnostic software for pathologists, primarily the Cleo platform with two CE-IVDR marked products: Cleo Breast (detects invasive and in situ carcinoma, mitoses, calcifications, and lymph node metastases on breast tissue whole slide images) and Cleo Skin (detects melanoma, squamous cell carcinoma, basal cell carcinoma with automated lesion and margin measurements on skin tissue). The software is sold as enterprise site licenses and is integrated into existing digital pathology Image Management Systems to automate biomarker scoring and speed cancer diagnosis.
Is Primaa a public or private company?
Primaa is a private company. It is classified as venture growth investor backed and is currently operating.
When was Primaa founded?
Primaa was founded in 2018. It employs 11 to 50 people.
Where is Primaa based?
Primaa is headquartered in Paris, France, in the Europe region.
How does Primaa make money?
Two revenue lines are on record. AI Software Licensing is the primary driver. The others are technology Partnership Licensing.
Who are Primaa's main competitors?
Gestalt Diagnostics is listed as a regional player. Broad incumbents are Indica Labs and Proscia. Emerging players are Mindpeak, Aiosyn and Lumea. Direct peers are Paige, Owkin, PathAI and Ibex Medical Analytics.
Does Primaa have an API?
No public API is recorded for Primaa.
What industry is Primaa in?
Primaa's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow, with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 513210 and its SIC code is 7372.